New Monoclonal Antibody Approved to Prevent Respiratory Syncytial Virus (RSV) in Infants
The US Food and Drug Administration has approved a new monoclonal antibody called Enflonsia to help prevent infection with respiratory syncytial virus (RSV), the leading cause of hospitalization in infants. Developed by Merck, the therapy will be given as a single 105-milligram shot to protect newborns and infants from mild, moderate, or severe RSV for … Read more